Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
12.04
+0.39 (3.35%)
Aug 25, 2026, 4:00 PM EDT - Market closed
Zevra Therapeutics Employees
Zevra Therapeutics had 61 employees as of December 31, 2025. The number of employees increased by 2 or 3.39% compared to the previous year.
Employees
61
Change (1Y)
2
Growth (1Y)
3.39%
Revenue / Employee
$2,230,672
Profits / Employee
$938,475
Market Cap
714.98M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 61 | 2 | 3.39% | 61 | 0 |
| Dec 31, 2024 | 59 | -10 | -14.49% | 59 | 0 |
| Dec 31, 2023 | 69 | 33 | 91.67% | 65 | 4 |
| Dec 31, 2022 | 36 | 12 | 50.00% | 32 | 4 |
| Dec 31, 2021 | 24 | 2 | 9.09% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Phathom Pharmaceuticals | 371 |
| REGENXBIO | 371 |
| Allogene Therapeutics | 152 |
| BridgeBio Oncology Therapeutics | 106 |
| Prelude Therapeutics | 79 |
| Assembly Biosciences | 73 |
| CytomX Therapeutics | 69 |
ZVRA News
- 23 hours ago - Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium - GlobeNewsWire
- 4 days ago - Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - Zevra Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 18 days ago - Zevra Therapeutics price target lowered to $23 from $24 at Guggenheim - TheFly
- 20 days ago - Zevra Therapeutics price target raised to $28 from $25 at Citizens - TheFly
- 20 days ago - Zevra Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 20 days ago - Zevra Therapeutics Earnings release: Q2 2026 - Filings
- 20 days ago - Zevra Therapeutics Quarterly report: Q2 2026 - Filings